Hemophilia A
56 programs · 55 companies
Programs
56
Companies
55
Trials
57
MOAs
36
KIF18AiALKiIL-13iCD47iTNFiBTKiPCSK9iIL-17iHPK1iBCMA ADC
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Phase 1/2 | GPRC5D | ||
| BMY-2495 | Phase 3 | KRASG12D | ||
| Gozesotorasib | NDA/BLA | HER2 | ||
| Zenonesiran | Preclinical | DLL3 | ||
| TAK-8262 | NDA/BLA | Tau | ||
| DSN-5254 | Phase 1 | B7-H3 | ||
| BMR-8377 | Phase 1/2 | PCSK9 | ||
| Mavutuximab | Phase 2/3 | PI3Kα | ||
| Nidaratamab | Preclinical | RET | ||
| COR-9566 | Approved | TYK2 | ||
| Terazumab | Phase 3 | AHR | ||
| CGO-2579 | Approved | TIGIT | ||
| SLD-2973 | NDA/BLA | KIF18A | ||
| CSL-7919 | Preclinical | BTK | ||
| Rilutenlimab | Phase 2 | GIP-R | ||
| Voxarapivir | Phase 2 | GPRC5D | ||
| SAM-IIT-777 | Phase 1 | PLK4 | ||
| EOR-IIT-912 | Phase 1 | TNFα | ||
| UCL-IIT-448 | Phase 1 | PD-L1 | ||
| INS-6048 | NDA/BLA | CD20 | ||
| Elraratamab | Phase 1 | PCSK9 | ||
| ACO-697 | Phase 1/2 | TIM-3 | ||
| Mirisotorasib | Phase 1/2 | PRMT5 | ||
| CAL-4725 | Preclinical | WEE1 | ||
| Mavucagene | Phase 1/2 | VEGF | ||
| Adagrafotisoran | Phase 2/3 | IL-17A | ||
| MNO-1564 | Phase 3 | B7-H3 | ||
| Polalemzoparlimab | Phase 1/2 | SMN2 | ||
| Pemifutibatinib | Phase 3 | BET | ||
| BIG-3814 | Approved | WRN | ||
| OCT-7288 | Phase 2/3 | CD123 | ||
| Niralemzoparlimab | Phase 2/3 | SOS1 | ||
| Olpanaritide | Phase 2/3 | CGRP | ||
| IVE-3532 | Phase 1 | CDK2 | ||
| FRE-IIT-416 | Phase 2 | TROP-2 | ||
| 418-9392 | NDA/BLA | MALT1 | ||
| Bemasacituzumab | Phase 1/2 | TROP-2 | ||
| 618-5050 | Phase 2 | IL-17A | ||
| Lirazasiran | Phase 3 | KRASG12D | ||
| Lisonaritide | Preclinical | CD20 | ||
| Bemavorutinib | Preclinical | PCSK9 | ||
| RCE-2070 | Phase 1/2 | FGFR | ||
| NYK-4396 | Preclinical | PD-L1 | ||
| Datozanubrutinib | Phase 2 | CGRP | ||
| Mavulucimab | NDA/BLA | CGRP | ||
| Polalemzoparlimab | Approved | GPRC5D | ||
| ASA-IIT-449 | Approved | FLT3 | ||
| FUD-IIT-133 | Phase 1/2 | VEGF | ||
| RUI-IIT-267 | Approved | PD-L1 | ||
| NAT-IIT-211 | Phase 3 | AuroraA | ||
| CTT-403 | Phase 1 | JAK2 | ||
| 600-3422 | Phase 1 | KRASG12D | ||
| Tirasertib | Phase 2/3 | IL-13 | ||
| EUP-4341 | Preclinical | TIM-3 | ||
| Riluzumab | Approved | SHP2 | ||
| Cevivorutinib | Phase 2/3 | KIF18A |
Trials (57)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06974514 | Pexatenlimab | Phase 1/2 | Completed |
| NCT05368713 | Gozesotorasib | NDA/BLA | Not yet recr... |
| NCT06285794 | Gozesotorasib | NDA/BLA | Recruiting |
| NCT04907615 | Zenonesiran | Preclinical | Completed |
| NCT06847866 | TAK-8262 | NDA/BLA | Not yet recr... |
| NCT03572481 | TAK-8262 | NDA/BLA | Completed |
| NCT05255097 | DSN-5254 | Phase 1 | Not yet recr... |
| NCT04124487 | DSN-5254 | Phase 1 | Completed |
| NCT03453657 | Mavutuximab | Phase 2/3 | Recruiting |
| NCT08533319 | Mavutuximab | Phase 2/3 | Not yet recr... |
| NCT03973894 | Nidaratamab | Preclinical | Recruiting |
| NCT05862647 | Nidaratamab | Preclinical | Terminated |
| NCT04104768 | Terazumab | Phase 3 | Not yet recr... |
| NCT05649699 | CGO-2579 | Approved | Terminated |
| NCT07839774 | CGO-2579 | Approved | Recruiting |
| NCT07230849 | CGO-2579 | Approved | Completed |
| NCT03406222 | SLD-2973 | NDA/BLA | Not yet recr... |
| NCT04759861 | Rilutenlimab | Phase 2 | Not yet recr... |
| NCT03471954 | Voxarapivir | Phase 2 | Recruiting |
| NCT07890561 | SAM-IIT-777 | Phase 1 | Active |